Two eyes, two lasers, same patient: Schwind's ESIRIS versus Wavelight's 400Q

Article

Schwind's ESIRIS and Wavelight's 400Q laser systems are equally efficacious in correcting refractive error, according to a study presented by Yannis Aslanides, MD of the Emmetropia Mediterranean Eye Clinic in Crete, Greece.

Schwind's ESIRIS and Wavelight's 400Q laser systems are equally efficacious in correcting refractive error, according to a study presented by Yannis Aslanides, MD of the Emmetropia Mediterranean Eye Clinic in Crete, Greece.

The Wavelight system produces a 400 Hz laser repetition rate versus the 200 Hz rate of Schwind's ESIRIS. Other key technological features include eyetracking (400Q: semi auto eyetracker with locking system, ESIRIS: full auto eyetracker with no locking system) and low energy at focus level (400Q: around 1.60 mJ, ESIRIS: around 0.50 mJ).

Aslanides and a team of colleagues studied the performance and safety of these two excimer laser platforms in 23 patients (13 males, 10 female; age 21-59 years), with each patient receiving treatment in both eyes, but one eye with ESIRIS and the second with 400Q. Both eyes were treated at the same session.

The team performed LASIK in 42 of the 46 eyes and PRK in the remaining four eyes. The Moria M2 microkeratome was employed for each LASIK procedure.

Postoperatively, subjects achieved uncorrected visual acuity (UCVA) of 0.7 to 1.5 (preoperative range was counting fingers to 0.6) and best-corrected visual acuity (BCVA) of 0.9 to 1.5, versus a preoperative BCVA of 0.7 to 1.2. Spherical equivalent (SE) refraction was recorded at -1.25 to plano postoperatively, from a preoperative SE refraction of -7.625 to +4.75.

Overall, 75% and 83% of ESIRIS and Wavelight eyes, respectively, were within ±0.5 D of target refraction. Of the remaining ESIRIS eyes, 100% were within 0.75 D of target, while 91.5% of remaining 400Q eyes were within 0.75D and 100% within 1 D of target refraction.

Aslanides conceded that there was no significant difference between the platforms in terms of refractive outcomes, with no adverse events or loss of UCVA or BCVA being recorded for either platform.

He concluded that both Schwind's ESIRIS and Wavelight's 400Q laser platforms were safe and effective for primary refractive corrections and the laser repetition rate does not appear to be important in achieving accurate visual outcomes.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.